期刊
ONCOTARGET
卷 7, 期 22, 页码 33440-33450出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.7961
关键词
glioblastoma; EGFR; PI3K/Akt/mTOR pathway; targeted therapy
资金
- Natural Science Foundation of China [81300800, 81302192, 81130042, 31171323]
- Liaoning research fund for higher education [20131141, 20141029]
- Ph.D. Programs Foundation of Ministry of Education of China [20132104120015]
Glioblastoma multiform (GBM) is the most common malignant glioma of all the brain tumors and currently effective treatment options are still lacking. GBM is frequently accompanied with overexpression and/or mutation of epidermal growth factor receptor (EGFR), which subsequently leads to activation of many downstream signal pathways such as phosphatidylinositol 3-kinase (PI3K)/Akt/rapamycinsensitive mTOR-complex (mTOR) pathway. Here we explored the reason why inhibition of the pathway may serve as a compelling therapeutic target for the disease, and provided an update data of EFGR and PI3K/Akt/mTOR inhibitors in clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据